NASDAQ · Biotechnology

AMGN

Amgen Inc · $229.92B
442.88
+4.14%

Price

252 sessions shown
1M3M6M1Y2Y5Y

Technicals

from daily closes
RSI · 14 day
80.8
Avg true range · 14d
2.72%
Volatility · 20d annualised
29.1%
Trend · 20d vs 50d
Up
vs 20-day average
10.19%
vs 50-day average
18.05%
vs 200-day average
26.02%
200-day average
351.44

Internals

where it sits, and how hard it is being traded
52-week low
269.77
52-week high
427.39
Volume vs its 20-day avg
0.61×
Beta vs the market
0.41
Sitting 110% of the way up its 52-week range (269.77427.39)

Swings

prices it actually turned at — highest or lowest of the surrounding 11 sessions
Turned down · Jun 11
358.46
Turned down · Jul 7
375.25
Turned down · Jul 28
398.00
Turned up · Jun 2
322.30
Turned up · Jun 18
334.05
Turned up · Jul 15
353.95

Fundamentals

P/E
25.84
Fwd P/E
P/S
5.93
P/B
20.36
EV/EBITDA
17.82
ROE
89.3%
ROA
9.5%
Gross margin
74.3%
Net margin
Debt / equity
6.31
Rev growth
9.1%
EPS growth
5.5%

Earnings

next report after the close
Next report
Nov 2, 2026
EPS expected
5.91
Beat in last 4
4 of 4
2026-06-30reported 6.29 vs 5.73 expected+9.8%
2026-03-31reported 5.15 vs 4.85 expected+6.1%
2025-12-31reported 5.29 vs 4.83 expected+9.6%
2025-09-30reported 5.64 vs 5.11 expected+10.3%

Analyst coverage

43 analysts · as of 2026-08-01
Strong buy
6
Buy
15
Hold
19
Sell
2
Strong sell
1

News

stories naming this company, last 21 days
Argus Research Maintains Buy on Amgen, Raises Price Target to $460 · Benzinga · Aug 19
Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026 · Benzinga · Aug 18
Mizuho Maintains Neutral on Amgen, Raises Price Target to $352 · Benzinga · Aug 18
Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $400 · Benzinga · Aug 18
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380 · Benzinga · Aug 14
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions · Yahoo · Aug 13

Every figure here is measured from live market data as of Aug 19, 07:40 PM. Nothing is estimated or filled in — where a figure shows the source had no value for it, and a section you don’t see had no data at all. This describes what the market has already done. It is not a forecast, and not financial advice.

← Scan for anotherSee the decision card →